Athira Pharma, INC Form 4 insider transactions
LeonaBio's Chief Medical Officer, Javier San Martin, sold 1,720 shares of common stock to cover tax obligations following the vesting of 7,418 restricted stock units.
Athira Pharma's Chief Medical Officer, Javier San Martin, executed a mandatory 'sell to cover' transaction, disposing of 1,644 common shares at a weighted-average price of $6.88 following RSU vesting.
Athira Pharma's President and CEO, Mark James Litton, reported the vesting of restricted stock units and a subsequent 'sell to cover' transaction for tax obligations.
Athira Pharma's Chief Financial Officer, Robert Renninger, reported recent acquisitions of common stock through an employee plan and a sale of shares to cover tax obligations related to RSU vesting.
Athira Pharma's Chief Scientific Officer, Kevin Church, reported recent stock acquisitions through an employee plan and RSU vesting, alongside a sale to cover tax obligations.
Athira Pharma's General Counsel, Mark Worthington, sold 876 shares of common stock to cover tax obligations following the vesting of restricted stock units.
Athira Pharma's Chief Financial Officer, Robert Renninger, was granted options to purchase 34,358 shares of common stock with an exercise price of $4.07.
Athira Pharma's President and CEO, Mark James Litton, was granted options to purchase 133,526 shares of common stock with an exercise price of $3.81.
Athira Pharma's Chief Scientific Officer, Kevin Church, was granted options to purchase 35,138 shares of common stock at an exercise price of $4.07.
Athira Pharma's Chief Medical Officer, Javier San Martin, was granted 44,508 stock options with an exercise price of $4.07, subject to vesting conditions.
Athira Pharma's General Counsel and CCO, Mark Worthington, was granted options to purchase 34,358 shares of common stock with an exercise price of $4.07, vesting based on performance and service.
Perceptive Advisors and affiliated funds significantly increased their beneficial ownership in Athira Pharma, acquiring common stock and various warrants.
Athira Pharma's Chief Scientific Officer, Kevin Church, reported recent acquisitions of common stock through the company's Employee Stock Purchase Plan and Restricted Stock Unit vesting, alongside a non-discretionary sale to cover tax obligations.
Athira Pharma, Inc.'s President and CEO, Mark James Litton, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.
Athira Pharma's Chief Medical Officer, Javier San Martin, reported the vesting of Restricted Stock Units and a subsequent non-discretionary sale of shares to cover tax obligations.
Athira Pharma's General Counsel, Mark Worthington, reported the acquisition of common stock through RSU vesting and a subsequent sale of shares to cover tax obligations.
Robert Renninger, SVP of Finance and Accounting at Athira Pharma, Inc., reported recent acquisitions of common stock through an employee stock purchase plan and RSU vesting, alongside a sale to cover tax obligations.
Athira Pharma, Inc. Director John M. Fluke Jr. was granted 20,900 stock options with an exercise price of $0.3125, vesting based on time or the next annual meeting, as part of the company's outside director compensation policy.
Athira Pharma, Inc. Director Michael A. Panzara was granted 20,900 stock options with an exercise price of $0.3125, aligning his interests with shareholder value.
Athira Pharma, Inc. Director Kelly A. Romano was granted 20,900 stock options with an exercise price of $0.3125, as disclosed in a recent SEC Form 4 filing.
Joseph Edelman, a Director and 10% Owner of Athira Pharma, Inc., was granted 20,900 stock options as part of the company's Outside Director Compensation Policy.
Athira Pharma, Inc. Director James A. Johnson was granted 20,900 stock options with an exercise price of $0.3125 as part of the company's outside director compensation policy.
Athira Pharma, Inc. Director Barbara Kosacz was granted 20,900 stock options with an exercise price of $0.3125, vesting based on time or the next annual meeting, as part of the company's outside director compensation policy.
Athira Pharma, Inc. Director Grant Pickering was granted 20,900 stock options with an exercise price of $0.3125, aligning his interests with the company's long-term performance.
Robert Renninger, SVP of Finance and Accounting at Athira Pharma, files an amended SEC Form 4 to correct the vesting schedule of a previously reported stock option award.
Kevin Church, Chief Scientific Officer of Athira Pharma, reports the acquisition of stock options and restricted stock units.
Mark Litton, CEO of Athira Pharma, acquired stock options for 333,815 shares and 222,543 restricted stock units on March 3, 2025.
Robert Renninger, SVP of Finance and Accounting at Athira Pharma, reports the acquisition of stock options and restricted stock units.
Chief Medical Officer Javier San Martin acquired stock options and restricted stock units in Athira Pharma, according to a recent SEC filing.
Mark Worthington, General Counsel and CCO of Athira Pharma, received stock options and restricted stock units on March 3, 2025, according to a Form 4 filing.